Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03706235 · ClinicalTrials.gov registry record
Colvera for Detection of Disease Recurrence
A clinical trial of Colorectal Adenocarcinoma, sponsored by Clinical Genomics Pathology.
- Completed
- Registry status
- 488
- Enrollment target
- 12
- Study locations
NCT03706235: Completed study of Colorectal Adenocarcinoma, sponsored by Clinical Genomics Pathology.
NCT03706235 is a study of Colorectal Adenocarcinoma that has completed, run by Clinical Genomics Pathology. The registered enrollment target is 488 participants, above the 293-participant average among 19 other Colorectal Adenocarcinoma trials with a reported enrollment target (67% higher). The trial reports 12 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03706235, a study of Colorectal Adenocarcinoma, has completed, sponsored by Clinical Genomics Pathology.
- COMPLETED
- Registry status
- 488 participants
- Enrollment target
- 12
- Study locations
Study Summary
To compare the sensitivity and specificity estimates of Colvera with that of a commercially available CEA test for detection of recurrent disease in CRC subjects who are undergoing surveillance for recurrence.
Primary Outcome
on positive or negative Colvera and CEA test results
Conditions Studied
Interventions
- OTHER Blood draw (venipuncture)
Study Locations (12)
Illinois
- Rush University Medical Center - Chicago
- NorthShore Health System - Evanston
California
- Torrance Memorial Physician Network - Redondo Beach
Delaware
- Bayhealth - Dover
Indiana
- Indiana University - Indianapolis
Louisiana
- Colon and Rectal Surgery Associates - Metairie
Michigan
- Providence Hospital-Ascension Health - Novi
Minnesota
- Virginia Piper Cancer Institute-Allina Health - Minneapolis
New Jersey
- Essex Oncology - Belleville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 488 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2020-04-29 |
What the finished NCT03706235 record still lists
NCT03706235 is an observational study that tracks outcomes without assigning an intervention. The registered 488 participants enrollment target is mid-sized for trials with a published cap, above the 293-participant average among 19 other Colorectal Adenocarcinoma trials with a reported enrollment target (67% higher).
The record links to 1 condition, with Colorectal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Blood draw (venipuncture) is the first listed.
NCT03706235 lists 12 locations in 11 states (Illinois, California, Delaware).
Frequently Asked Questions
What is clinical trial NCT03706235 about?
NCT03706235 is a clinical study titled "Colvera for Detection of Disease Recurrence". To compare the sensitivity and specificity estimates of Colvera with that of a commercially available CEA test for detection of recurrent disease in CRC subjects who are undergoing surveillance for recurrence.
What is the current status of trial NCT03706235?
This trial is currently completed. The enrollment target is 488 participants. The study started on 2018-02-01. Estimated completion is 2020-04-29.
What conditions does trial NCT03706235 study?
This clinical trial studies the following conditions: Colorectal Adenocarcinoma.
What interventions are being tested in trial NCT03706235?
The interventions under investigation include: Blood draw (venipuncture) (OTHER).
Who is sponsoring clinical trial NCT03706235?
This trial is sponsored by Clinical Genomics Pathology, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03706235 being conducted?
This trial has 12 study locations across California, Delaware, Illinois, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03706235's enrollment target sits among peer trials
488 3rd of 19 higher than 17 of 19 other Colorectal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RECRUITING · Phase 1
-
Early Onset Colorectal Cancer Detection
RECRUITING
-
Stage II/III Colorectal Cancer Recurrence
RECRUITING
-
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05154669 · 488 participants · Phase 3
Integrating Financial Coaching and Smoking Cessation Coaching
- NCT06532877 · 488 participants · NA
Telephone Support in Advanced Gastrointestinal Cancer
- NCT06602479 · 488 participants · Phase 2
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
- NCT06794983 · 488 participants · NA
Calls and Coordination for Transitions of Care at Re-entry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI